Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

by Peter Y Yu, Heather L Gardner, Ryan Roberts, Hakan Cam, Seethalakshmi Hariharan, Ling Ren, Amy K LeBlanc, Hui Xiao, Jiayuh Lin, Denis C Guttridge, Xiaokui Mo, Chad E Bennett, Christopher C Coss, Yonghua Ling, Mitch A Phelps, Peter Houghton, Cheryl A London
Published 2017-01-01